Generic Medicine Info
Indications and Dosage
Gynaecological infections, Intra-abdominal infections, Skin and skin structure infections
Adult: 1.5 g (1 g ampicillin/0.5 g sulbactam) -3 g (2 g ampicillin/1 g sulbactam) every 6 hr. Max: 4 g sulbactam/day.
Child: ≥1 yr: 300 mg/kg daily (200 mg ampicillin/100 mg sulbactam), given via IV infusion in equally divided doses every 6 hr. ≥40 kg: 1.5 g (1 g ampicillin/0.5 g sulbactam) -3 g (2 g ampicillin/1 g sulbactam) IM/IV every 6 hr. Max treatment duration: 14 days.

Acute pelvic inflammatory disease
Adult: 3 g (2 g ampicillin/1 g sulbactam) every 6 hr with doxycycline. Discontinue IV therapy 24 hr after clinical improvement; continue with oral doxycycline (100 mg bid) for 14 days to complete treatment.
Renal Impairment
Dose reduction is required.
Special Precautions
Hepatic disease, biliary obstruction, ingestion of alcohol, pregnancy and lactation.
Adverse Reactions
GI disturbances; hypersensitivity.
Potentially Fatal: Stevens-Johnson syndrome.
Drug Interactions
Probenecid may increase the serum concentrations of sulbactam.
Description: Sulbactam, a penicillanic acid sulfone with β-lactamase inhibitory properties has weak antibacterial activity, but is an irreversible inhibitor of many plasmid-mediated and some chromosomal β-lactamases. It has a similar spectrum of β-lactamase inhibition to clavulanic acid, although it is less potent. It enhances the activity of penicillins and cephalosporins. It is usually given with ampicillin to increase the antimicrobial spectrum; may also be used with cefoperazone.
Absorption: Poorly absorbed from the GI tract.
Distribution: Distributed into breast milk. Protein binding: 38%.
Excretion: Half-life elimination: 1-1.3 hr. About 75-85% is excreted unchanged in the urine within 8 hr.
Sterile powder for inj: Store below 20°C.
MIMS Class
Other Beta-Lactams
Disclaimer: This information is independently developed by MIMS based on Sulbactam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in